番茄社区

Oncology/Hematology

News, opinions and meeting coverage in oncology/hematology.

How ASCO'S First Clinical Trial -- TAPUR -- Came To Be

ASCO's entry will evaluate off-label use of targeted agents

ASCO: Gazyva Doubles Average Remission Time in NHL

Obinutuzumab delays progression in rituximab-refractory indolent disease.

Ibrance Delivers in Advanced Breast Ca

Palbociclib-fulvestrant combo leads to better PFS as second-line therapy

ASCO: Annual Meeting Emphasizes Advances, Challenges in Cancer

Largest program to date highlights developments in breast cancer, other malignancies

ASCO: Chemo-ADT Combo Still Winning in Prostate Cancer

Yet another report of survival improvement with upfront docetaxel plus hormonal therapy.

Antitibiotic-Chemo Combo Cuts Infection Risk in AML

Incidence of Streptococcus viridans more than halved with prophylaxis.

Injecting Opioid Tied to Blood Clotting Disorder

Are most clinicians aware of this side effect of oxymorphone drug abuse?

ACP Prefers Cervical Cytology Over DNA Screens for Young Women

HPV testing in women under 30 could cause more harm than good, group says.

Part 2: Oncologists Weigh In on PBS Cancer Documentary

Six specialists share their impressions of Ken Burns' cancer opus.

Brain Cancer: Did '60 Minutes' Report Raise False Hope?

Glioblastoma virotherapy touted on CBS program is promising but preliminary.

AAD: Frog Enzyme Clears Genital Warts

Summaries of late-breaking research from the dermatology meeting.

Frankie the Dog Fetches - and Finds Thyroid Cancer?

Canine trained in cancer scent detection gives few false positives in early test.

Seeds Top EBRT as Boost Tx in Prostate Cancer

And other advances in prostate cancer care from the Genitourinary Cancers Symposium.

HDAC Inhibitor OK'd for Multiple Myeloma

Panobinostat targets histone deacetylases; first of its kind to win approval in myeloma.

Predicting Death in Advanced Cancer

Study offers clues to guide clinicians, families about end of life.

CRC Regimens Give Survival Bump in Second Line

Ramucirumab trial meets primary endpoint; famitinib offers respectable disease control rate.

More Drugs, Better Survival in Metastatic Colon Cancer

Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival.

Scoring System for Lung Cancer Screening Debuts

Radiologists to get tools for grading suspicious lesions.

Mammograms: Less Pain, Risk-Based Screens?

Breast cancer screening after 40, a more comfortable mammogram.

Clinical Focus In Renal Cell Carcinoma: Clues from Gene Studies

Mutations in four genes appear to play a key role in the origin of renal cell carcinoma.

No Need for Cancer Watch in Cirrhotic Wilson's Disease

Hepatocellular carcinoma is too infrequent to merit regular surveillance.

Evolution: Breast Reconstruction After Mastectomy

Techniques have changed and improved.

Do Statins Up a Woman's Risk for Thyroid Cancer?

Estrogen may neutralize the cancer-protective effects of cholesterol-lowering drugs.

That's Not Chronic Lyme, It's Cancer

Three case reports demonstrate the risks of "assuming that patients have chronic Lyme disease."

'Yes' to Routine Colonoscopies in IBD

Screening lowered colorectal cancer incidence and colon cancer mortality.

Case Study: Fecal Transplant Clears K. Pneumoniae

Treatment of teenage girl suggests another use for fecal microbiota transplant.

BCS: 'Jolie Effect' Drives Genetic Test Referrals

SAN FRANCISCO -- Referrals for genetic testing almost doubled in the first 6 months after actress Angelina Jolie said she would undergo bilateral mastectomy after testing positive for BRCA1 mutation.

New Melanomas Likely to Recur at Same Rate

CHICAGO -- A diagnosis of in situ or invasive melanoma conferred a similar long-term risk of invasive melanoma recurrence, a 40-year retrospective review showed.

Are Your Patients Using Fake Names?

A case study in the American Journal of Medicine poses a vexing question many healthcare professionals have faced: What should you do when your patients use fraudulent names?

Morning Break: The B.O. Talk, No Love for Niacin

Health news and commentary from around the Web, gathered by the 番茄社区 staff.

Friday Feedback: Zero-Tolerance Employment Smoking Bans?

Should hospitals, schools, and companies refuse to hire smokers for teachers and healthcare providers?

FDA Panel Puts Brakes on Anti-PARP Drug

WASHINGTON -- Approval of a PARP inhibitor for patients with advanced ovarian cancer should await results of an ongoing clinical trial that has the potential to answer questions about the drug's safety and efficacy, according to an FDA advisory committee that voted against immediate approval.

AMA Clamps Down on MOC, But Punts on Gun Regs

CHICAGO -- The AMA鈥檚 House of Delegates drew the line on this year's hot button topic -- maintenance of certification (MOC), saying it should not be mandatory, nor should it be a condition of licensure.

ASCO: Myeloma Study Results Inconclusive

CHICAGO -- A trial comparing two immunomodulatory regimens for myeloma failed to demonstrate noninferiority for the newer drug.

ASCO: Combo Extends PFS in Relapsed Myeloma

CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed.

ASCO: Targeting PD-1 Works in Advanced Melanoma

CHICAGO -- Two studies indicate that using investigative immunotherapy drugs improves survival and response in patients with metastatic melanoma, researchers said here.

ASCO: Antibody Adds 6 Weeks to Squamous NSCLC Survival

CHICAGO -- The novel anti-EGFR monoclonal antibody necitumumab modestly improved survival in squamous non-small cell lung cancer (NSCLC) in a pivotal trial, but many called the effect too small to count.

ASCO: Targeted Combo Extends PFS in Ovarian Ca

CHICAGO -- Progression-free survival almost doubled in women with platinum-sensitive relapsed ovarian cancer treated with two targeted drugs instead of one, investigators reported here.

ASCO: Ipilimumab Cuts Relapse but Safety Issues Remain

CHICAGO -- High-risk melanoma patients have a reduced level of relapse if they are taking the monoclonal antibody ipilimumab (Yervoy) when compared with placebo, researchers said here.

Medtronic's Infuse Moves From Operating Room to Courtroom

An investigative series by 番茄社区/Milwaukee Journal Sentinel has been tracking the spinal fusion device called Infuse in a 4-year-long series and now reports how a flawed FDA system for device approval may have led to a long string of adverse events culminating in thousands of liability suits.

鈥�

70

鈥�